Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis.

Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH.

Clin Lung Cancer. 2018 Aug 22. pii: S1525-7304(18)30206-7. doi: 10.1016/j.cllc.2018.08.012. [Epub ahead of print]

PMID:
30197263
2.

Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy.

Cushman TR, Caetano MS, Welsh JW, Verma V.

Immunotherapy. 2018 Aug;10(10):851-0. doi: 10.2217/imt-2018-0019.

PMID:
30073899
3.

Addictions Training in General Psychiatry Training Programs: Current Gaps and Barriers.

Schwartz AC, Frank A, Welsh JW, Blankenship K, DeJong SM.

Acad Psychiatry. 2018 Aug 2. doi: 10.1007/s40596-018-0950-2. [Epub ahead of print]

PMID:
30073538
4.

Addictions Training in Child and Adolescent Psychiatry Fellowships.

Welsh JW, Schwartz AC, DeJong SM.

Acad Psychiatry. 2018 Jul 31. doi: 10.1007/s40596-018-0959-6. [Epub ahead of print]

PMID:
30066242
5.

Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials.

Verma V, Cushman TR, Selek U, Tang C, Welsh JW.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1141-1148. doi: 10.1016/j.ijrobp.2018.04.054. Epub 2018 Apr 27.

PMID:
30012526
6.

Hematologic variables associated with brain failure in patients with small-cell lung cancer.

Suzuki R, Wei X, Allen PK, Welsh JW, Komaki R, Lin SH.

Radiother Oncol. 2018 Sep;128(3):505-512. doi: 10.1016/j.radonc.2018.05.026. Epub 2018 Jun 12.

PMID:
29907337
7.

Review: Adjunctive pharmacologic approaches for benzodiazepine tapers.

Welsh JW, Tretyak V, McHugh RK, Weiss RD, Bogunovic O.

Drug Alcohol Depend. 2018 Aug 1;189:96-107. doi: 10.1016/j.drugalcdep.2018.04.028. Epub 2018 May 31. Review.

PMID:
29906718
8.

Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.

Niknam S, Barsoumian HB, Schoenhals JE, Jackson HL, Yanamandra N, Caetano MS, Li A, Younes AI, Cadena A, Cushman TR, Chang JY, Nguyen QN, Gomez DR, Diab A, Heymach JV, Hwu P, Cortez MA, Welsh JW.

Clin Cancer Res. 2018 May 21. doi: 10.1158/1078-0432.CCR-17-3279. [Epub ahead of print]

PMID:
29784675
9.

Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.

Li A, Barsoumian HB, Schoenhals JE, Cushman TR, Caetano MS, Wang X, Valdecanas DR, Niknam S, Younes AI, Li G, Woodward WA, Cortez MA, Welsh JW.

Cancer Lett. 2018 Sep 1;431:54-63. doi: 10.1016/j.canlet.2018.05.005. Epub 2018 May 8.

PMID:
29746927
10.

Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy.

Kim CR, Kim B, Ning MS, Reddy JP, Liao Z, Tang C, Welsh JW, Mott FE, Shih YT, Gomez DR.

Clin Lung Cancer. 2018 Jul;19(4):e517-e528. doi: 10.1016/j.cllc.2018.03.012. Epub 2018 Mar 17.

PMID:
29685701
11.

The Opioid Crisis and Schools-A Commentary.

Welsh JW, Tretyak V, Rappaport N.

J Sch Health. 2018 May;88(5):337-340. doi: 10.1111/josh.12617. No abstract available.

PMID:
29609215
12.

Combining radiation plus immunotherapy to improve systemic immune response.

Cushman TR, Gomez D, Kumar R, Likacheva A, Chang JY, Cadena AP, Paris S, Welsh JW.

J Thorac Dis. 2018 Feb;10(Suppl 3):S468-S479. doi: 10.21037/jtd.2018.01.130. Review.

13.

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.

Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA.

Genome Res. 2018 Apr;28(4):432-447. doi: 10.1101/gr.225128.117. Epub 2018 Mar 22.

PMID:
29567676
14.

Radiation therapy and immunotherapy: what is the optimal timing or sequencing?

Aliru ML, Schoenhals JE, Venkatesulu BP, Anderson CC, Barsoumian HB, Younes AI, K Mahadevan LS, Soeung M, Aziz KE, Welsh JW, Krishnan S.

Immunotherapy. 2018 Feb 1;10(4):299-316. doi: 10.2217/imt-2017-0082.

PMID:
29421979
15.

Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer.

Suzuki R, Lin SH, Wei X, Allen PK, Welsh JW, Byers LA, Komaki R.

Radiother Oncol. 2018 Mar;126(3):499-505. doi: 10.1016/j.radonc.2017.12.030. Epub 2018 Feb 2.

PMID:
29398150
16.

Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer.

Tang C, Hobbs B, Amer A, Li X, Behrens C, Canales JR, Cuentas EP, Villalobos P, Fried D, Chang JY, Hong DS, Welsh JW, Sepesi B, Court L, Wistuba II, Koay EJ.

Sci Rep. 2018 Jan 31;8(1):1922. doi: 10.1038/s41598-018-20471-5.

17.

Radiation and Anti-Cancer Vaccines: A Winning Combination.

Cadena A, Cushman TR, Anderson C, Barsoumian HB, Welsh JW, Cortez MA.

Vaccines (Basel). 2018 Jan 30;6(1). pii: E9. doi: 10.3390/vaccines6010009. Review.

18.

Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer.

Pezzi TA, Schwartz DL, Mohamed ASR, Welsh JW, Komaki RU, Hahn SM, Sepesi B, Pezzi CM, Fuller CD, Chun SG.

JAMA Oncol. 2018 Aug 1;4(8):e174504. doi: 10.1001/jamaoncol.2017.4504. Epub 2018 Aug 9.

PMID:
29302695
19.

Adherence to Methodological Standards in Research Using the National Inpatient Sample.

Khera R, Angraal S, Couch T, Welsh JW, Nallamothu BK, Girotra S, Chan PS, Krumholz HM.

JAMA. 2017 Nov 28;318(20):2011-2018. doi: 10.1001/jama.2017.17653.

PMID:
29183077
20.

Merits of Data Sharing: The Digitalis Investigation Group Trial.

Angraal S, Ross JS, Dhruva SS, Desai NR, Welsh JW, Krumholz HM.

J Am Coll Cardiol. 2017 Oct 3;70(14):1825-1827. doi: 10.1016/j.jacc.2017.07.786. No abstract available.

PMID:
28958337
21.

Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.

An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J.

Radiother Oncol. 2017 Oct;125(1):80-88. doi: 10.1016/j.radonc.2017.08.009. Epub 2017 Sep 12.

PMID:
28916225
22.

Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival.

Kono M, Allen PK, Lin SH, Wei X, Jeter MD, Welsh JW, Cox JD, Komaki R.

J Thorac Oncol. 2017 Nov;12(11):1696-1703. doi: 10.1016/j.jtho.2017.07.030. Epub 2017 Aug 10.

PMID:
28804012
23.

Adolescent Frequent Heavy Drinking From 1991-2015.

Welsh JW, Knight JR, Hadland SE.

Pediatrics. 2017 Jun;139(6). pii: e20170932. doi: 10.1542/peds.2017-0932. No abstract available.

24.

Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation.

Schoenhals JE, Seyedin SN, Anderson C, Brooks ED, Li YR, Younes AI, Niknam S, Li A, Barsoumian HB, Cortez MA, Welsh JW.

Transl Lung Cancer Res. 2017 Apr;6(2):148-158. doi: 10.21037/tlcr.2017.03.06. Review.

25.

Optimizing Radiotherapy with Immunotherapeutic Approaches.

Schoenhals JE, Skrepnik T, Selek U, Cortez MA, Li A, Welsh JW.

Adv Exp Med Biol. 2017;995:53-71. doi: 10.1007/978-3-319-53156-4_3. Review.

PMID:
28321812
26.

Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer.

Brooks ED, Sun B, Zhao L, Komaki R, Liao Z, Jeter M, Welsh JW, O'Reilly MS, Gomez DR, Hahn SM, Heymach JV, Rice DC, Chang JY.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):900-907. doi: 10.1016/j.ijrobp.2016.12.022. Epub 2016 Dec 21.

27.

Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials.

Logan JK, Tang C, Liao Z, Lee JJ, Heymach JV, Swisher SG, Welsh JW, Zhang J, Lin SH, Gomez DR.

Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):770-777. doi: 10.1016/j.ijrobp.2016.11.035. Epub 2016 Nov 27.

28.

Association Between Substance Use Diagnoses and Psychiatric Disorders in an Adolescent and Young Adult Clinic-Based Population.

Welsh JW, Knight JR, Hou SS, Malowney M, Schram P, Sherritt L, Boyd JW.

J Adolesc Health. 2017 Jun;60(6):648-652. doi: 10.1016/j.jadohealth.2016.12.018. Epub 2017 Feb 12.

PMID:
28202303
29.

Phase I Trial: SABR and Ipilimumab-Response.

Tang C, Welsh JW, Hong D.

Clin Cancer Res. 2017 Jan 1;23(1):321. doi: 10.1158/1078-0432.CCR-16-2621. No abstract available.

30.

Bilateral Upper Extremity Cellulitis From Injecting Crack Cocaine Dissolved in Lemon Juice: A Case Report.

Welsh JW, Rodriguez C, Suzuki J.

Prim Care Companion CNS Disord. 2016 Oct 13;18(5). doi: 10.4088/PCC.16l01933. No abstract available.

31.

Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.

Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW.

Cancer Res. 2017 Feb 15;77(4):839-850. doi: 10.1158/0008-5472.CAN-15-3142. Epub 2016 Nov 7.

32.

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.

Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS.

Clin Cancer Res. 2017 Mar 15;23(6):1388-1396. doi: 10.1158/1078-0432.CCR-16-1432. Epub 2016 Sep 20.

33.

Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial.

Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU.

J Thorac Oncol. 2017 Feb;12(2):375-382. doi: 10.1016/j.jtho.2016.10.013. Epub 2016 Oct 26.

34.

Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity.

Chance WW, Nguyen QN, Mehran R, Welsh JW, Gomez DR, Balter P, Komaki R, Liao Z, Chang JY.

Pract Radiat Oncol. 2017 May - Jun;7(3):e195-e203. doi: 10.1016/j.prro.2016.09.005. Epub 2016 Sep 13.

PMID:
27743801
35.

Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.

Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW.

Cancer J. 2016 Jul-Aug;22(4):257-66. doi: 10.1097/PPO.0000000000000210. Review.

36.

Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control.

Schoenhals JE, Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouko E, Chang JY, Hahn SM, Welsh JW.

Cancer J. 2016 Mar-Apr;22(2):130-7. doi: 10.1097/PPO.0000000000000181. Review.

PMID:
27111909
37.

Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer.

Li P, Wang X, Liu Z, Liu H, Xu T, Wang H, Gomez DR, Nguyen QN, Wang LE, Teng Y, Song Y, Komaki R, Welsh JW, Wei Q, Liao Z.

Clin Lung Cancer. 2016 Jul;17(4):253-262.e5. doi: 10.1016/j.cllc.2015.11.008. Epub 2015 Nov 22.

PMID:
26732495
38.

In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation.

Cortez MA, Valdecanas D, Niknam S, Peltier HJ, Diao L, Giri U, Komaki R, Calin GA, Gomez DR, Chang JY, Heymach JV, Bader AG, Welsh JW.

Mol Ther Nucleic Acids. 2015 Dec 15;4:e270. doi: 10.1038/mtna.2015.47.

39.

PDL1 Regulation by p53 via miR-34.

Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW.

J Natl Cancer Inst. 2015 Nov 17;108(1). pii: djv303. doi: 10.1093/jnci/djv303. Print 2016 Jan.

40.

Strategies for combining immunotherapy with radiation for anticancer therapy.

Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW.

Immunotherapy. 2015;7(9):967-980. doi: 10.2217/imt.15.65. Epub 2015 Aug 27. Review.

41.

Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.

Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):317-24. doi: 10.1016/j.ijrobp.2015.02.005.

42.

Author's view: radiation and immunotherapy as systemic therapy for solid tumors.

Seyedin SN, Tang C, Welsh JW.

Oncoimmunology. 2015 Jan 20;4(3):e986402. eCollection 2015 Jan.

43.

Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy Strategies for Locally Advanced Non-Small-Cell Lung Cancer.

Selek U, Bölükbaşı Y, Welsh JW, Topkan E.

Balkan Med J. 2014 Dec;31(4):286-94. doi: 10.5152/balkanmedj.2014.14529. Epub 2014 Sep 13. Review.

44.

Prognostic significance of EGFR and KRAS mutations in NSCLC patients with brain metastases treated with radiosurgery.

Parikh NR, Likhacheva A, Pinnix C, Allen PK, Prabhu SS, Guha-Thakurta N, Welsh JW, Brown PD, Chang EL.

J Radiosurg SBRT. 2015;3(3):171-178.

45.

Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure.

Gomez DR, Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, Pan HY, Chang JY, Komaki R, Cox JD, McAleer MF, Grosshans DR.

J Thorac Oncol. 2014 Oct;9(10):1554-60. doi: 10.1097/JTO.0000000000000306.

46.

Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation.

Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR.

Clin Lung Cancer. 2015 Mar;16(2):156-63. doi: 10.1016/j.cllc.2014.10.005. Epub 2014 Oct 25.

PMID:
25467928
47.

Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer.

Xu T, Liao Z, O'Reilly MS, Levy LB, Welsh JW, Wang LE, Lin SH, Komaki R, Liu Z, Wei Q, Gomez DR.

Radiother Oncol. 2014 Dec;113(3):379-84. doi: 10.1016/j.radonc.2014.11.006. Epub 2014 Nov 25.

PMID:
25466375
48.

Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis.

Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z, Chang JY, Tang C, Pan HY, Welsh JW, Mehran RJ, Gomez DR.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):149-56. doi: 10.1016/j.ijrobp.2014.08.343. Epub 2014 Oct 25.

PMID:
25442335
49.

Galectin-1 and immune suppression during radiotherapy.

Welsh JW, Seyedin SN, Cortez MA, Maity A, Hahn SM.

Clin Cancer Res. 2014 Dec 15;20(24):6230-2. doi: 10.1158/1078-0432.CCR-14-2702. Epub 2014 Oct 27.

50.

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.

Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX.

Nat Commun. 2014 Oct 28;5:5241. doi: 10.1038/ncomms6241.

Supplemental Content

Loading ...
Support Center